Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer
Jun 11, 2020
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience
Oct 09, 2019
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA® (tildrakizumab-asmn) Maintained Over Four Years in People with Moderate-to-Severe Plaque Psoriasis
Jun 14, 2019
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA(TM) (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
Feb 27, 2019
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA(TM) for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
Oct 23, 2018
Sun Pharma Announces the Availability of ILUMYA(TM) (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
Mar 21, 2018
Sun Pharma Announces U.S. FDA Approval of ILUMYA(TM) (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
Feb 12, 2018
Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting
Oct 23, 2017
Sun Dermatology Launches ABSORICA® (isotretinoin) Tracker App to Help Patients Track Progress